湖北微观解剖肾脏模型(衢州舌苔模型) (今日更新中)

BEIJING, August 3 (Xinhuanet) -- Women who experience any form of gender-based violence are at greater risk of mental health disorders and related dysfunction and disability, according to Australian researchers Wednesday.Those who'd been through at least one form of this abuse -- which includes intimate partner violence, rape, sexual assault, or stalking -- were almost three times more likely to experience a mental health condition than those who were never victimized, according to Susan Rees, PhD of the University of New South Wales in Sydney, Australia, and her colleagues.Those who'd experienced three or four forms had an 11-fold greater risk, reported in the Aug. 3 issue of the Journal of the American Medical Association.The study "reveals a pattern of social disadvantage, disability, and impaired quality of life among women who have experienced gender-based violence," the researchers wrote.

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

HOHHOT, Aug. 27 (Xinhua) -- A 5,000-year old rock carving in north China's Inner Mongolia Autonomous Region depicts a falling meteor, said archaeologists on Saturday.A rock on the side of Dahei Mountain in the city of Chifeng has images of people, domed houses and a fire ball with a long tail falling from the sky engraved on it, said Wu Jiacai, head of the Inner Mongolia rock paintings protection association."I believe it shows prehistoric people returning at dusk from a hunting trip to their domed houses, as a meteor falls from the sky," Wu shared his findings at the 6th Hongshan Cultural Forum that runs from August 25 to 27.He added that in the same location several years ago, another set of carvings were found showing people fleeing, snakes slithering and birds flying away, which might be what happened after the meteor hit the earth.The area has about 1000 carvings all believed to be made by the Neolithic Hongshan people, Wu said."The pictures can shed some light on the disappearance of the Hongshan culture, which was quite developed," Wu said.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

WASHINGTON, Sept. 13 (Xinhua) -- The U.S. Department of Agriculture (USDA) announced Tuesday it will begin testing next year for six more kinds of E.coli bacteria in raw ground beef and tenderized steaks in order to protect the safety of the American food supply.The U.S. currently tests for one strain of E.coli O157:H7 in beef. According to the USDA, from March 5 next year, if the E. coli serogroups O26, O103, O45, O111, O121 and O145 are found in raw ground beef or its precursors, those products will be prohibited from entering commerce.Like E.coli O157:H7, these serogroups can cause severe illness and even death, and young children and the elderly are at highest risk."The Obama Administration is committed to protecting our food supply and preventing illnesses before they happen," said Agriculture Secretary Tom Vilsack in a statement. "Today's announcement does exactly that by targeting and eliminating contaminated products from the market.""Too often, we are caught reacting to a problem instead of preventing it. This new policy will help stop problems before they start," he said.About one in six Americans becomes sick from a food borne illnesses each year, an epidemic that kills about 3,000 annually and hospitalizes 128,000, according to the U.S. Centers for Disease Control and Prevention.

来源：资阳报